# Factor XI LICA to Reduce Events Such as Heart Attack and Stroke in Patients Whose Kidneys Are no Longer Able to Work as They Should and Require Treatment to Filter Wastes From the Blood: Focus is on the Safety of BAY2976217 and the Way the Body Absorbs, Distributes and Removes the Study Drug

> **NCT04534114** · PHASE2 · COMPLETED · sponsor: **Bayer** · enrollment: 307 (actual)

## Conditions studied

- End Stage Renal Disease Requiring Hemodialysis

## Interventions

- **DRUG:** Fesomersen sodium (BAY2976217)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04534114
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-04
- **Primary completion:** 2022-01-24
- **Final completion:** 2022-05-12
- **Target enrollment:** 307 (ACTUAL)
- **Last updated:** 2023-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04534114

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04534114, "Factor XI LICA to Reduce Events Such as Heart Attack and Stroke in Patients Whose Kidneys Are no Longer Able to Work as They Should and Require Treatment to Filter Wastes From the Blood: Focus is on the Safety of BAY2976217 and the Way the Body Absorbs, Distributes and Removes the Study Drug". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04534114. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*